An interventional study of Mindfulness in Mindfulness, Colon Cancer and Females, sponsored by University of Illinois Chicago. Completed at 1 site in United States. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of Illinois Chicago · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.
Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 601st largest by enrollment of the 865 interventional ones that give a count, is one of 26 that started in 2024, is one of 264 with no phase, and was the 1,041st registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
Solstice Oncology, Inc. · Sites in United States, Belgium, Italy and 3 more countries
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
Guardant Health, Inc. · Sites in United States
Ages 45–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 45 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 341 · Phase 3 87 · Phase 4 10
First in 1981; this study’s year is marked. 26 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 50 across the 865 interventional studies, 220 across the 181 observational. Of the 840 that completed or were terminated, 241 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
229 of 1,123 have an industry lead sponsor. The 10 most frequent:
University of Illinois Chicago is the lead sponsor of 31 studies on the registry; 19 are open to participants now.
University of Illinois Chicago has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
60 of the studies in Colonic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803553Phase 3Massachusetts General HospitalIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | 2026-12 |
| NCT06191185University of California, San FranciscoIMProving Adherence to Colonoscopy Through Teams and Technology | 2026-11-27 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,123 studies in Colonic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many neighborhoods in Chicago experience daily exposure to stressors including economic inopportunity and violent crime in public spaces. There is mounting evidence that chronic psychosocial stress can facilitate carcinogenesis by modulating the gut microbiome and immune system. The proposed research aims to study the practice of mindfulness to mitigate CPS and reduce colorectal cancer risk factors among Black American women at elevated risk.
Chronic stress can directly and indirectly promote carcinogenesis through immune, metabolic, and microbial pathways. Our overarching hypothesis is that reducing chronic stress will have important implications for colon cancer risk reduction among vulnerable and high-risk populations. A promising approach for reducing chronic stress is mindfulness practices. Mindfulness is a meditation-based technique to achieve a state of mind used to experience higher awareness or consciousness. We propose to pilot test an 8-week Mindfulness intervention delivered in a hybrid format (synchronous and asynchronous sessions) among 40 Black females at elevated risk of colon cancer, who reside in vulnerable communities and who report moderate to high perceived stress. At baseline and post-intervention, participants will provide blood and stool undergo body composition analysis, and complete mood and lifestyle-related surveys. The specific aims are to: test the feasibility and acceptability of the intervention and evaluate the preliminary effect on stress and weight, fasting glucose, inflammation markers, and the gut microbiome - risk markers and risk pathways associated with colon tumorigenesis. While relieving social stressors is the paramount goal, addressing chronic stress at the individual level is achievable now, with implications for CRC risk reduction. If successful, data generated here will serve in developing a fully powered trial to test if MBSR is efficacious for CRC risk reduction among high-risk vulnerable populations in Chicago.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8-week group and individual mindfulness training and practice
Behavioral: Mindfulness
Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
Recruitment Feasibility
Feasible if ≥ 30% of those approached enroll at a
Time frame: Monitored across the duration of trial (~12 months)
Percent of Participant Retained at Post-intervention Data Collection
% retained at post-intervention data collection
Time frame: Retention to post-intervention data collection, 8-9 weeks
% of Sessions Attended
% of sessions attended including the retreat
Time frame: week 1 through 8 including the retreat
Engagement With Mindfulness Website, Mean Weekly Minutes and Standard Deviation
Engagement with mindfulness website assessed as mean weekly minutes and standard deviation across the 8 week intervention
Time frame: Assessed weeks 1 - 8 of the mindfulness intervention.
Change in Body Mass Index
weight in kg divided by height in meters squared, pre - post intervention
Time frame: Baseline and post-intervention at week 9
Perceived Stress Scale Score
Change in perceived stress scale score between baseline and post-intervention, pre-post Scale is 0-40 with higher scores reflecting higher perceived stress.
Time frame: Baseline and post-intervention at week 9
Fasting Glucose
Change in serum fasting glucose between baseline and follow-up, pre - post
Time frame: Baseline and post-intervention at week 9
Hemoglobin A1c
Change from baseline to post-intervention in % glycated hemoglobin
Time frame: Baseline to post-intervention at week 9
Systolic Blood Pressure mmHg
Change in systolic blood pressure between baseline and post-intervention, pre - post
Time frame: from baseline to week 9
Diastolic Blood Pressure, mmHg
Change in diastolic blood pressure between baseline and post-intervention, pre - post
Time frame: baseline to week 9
| Milestone | Mindfulness |
|---|---|
| Started | 24 |
| Completed | 20 |
| Not completed | 4 |
Feasible if ≥ 30% of those approached enroll at a
| Participants | Mindfulness |
|---|---|
| Recruitment Feasibility | 24 |
% retained at post-intervention data collection
| Participants | Mindfulness |
|---|---|
| Percent of Participant Retained at Post-intervention Data Collection | 20 |
% of sessions attended including the retreat
| percentage | Mindfulness |
|---|---|
| % of Sessions Attended | 69.7 ± 19.7 |
Engagement with mindfulness website assessed as mean weekly minutes and standard deviation across the 8 week intervention
| minutes | Mindfulness |
|---|---|
| Engagement With Mindfulness Website, Mean Weekly Minutes and Standard Deviation | 30.33 ± 38.12 |
weight in kg divided by height in meters squared, pre - post intervention
| kg/m^2 | Mindfulness |
|---|---|
| Change in Body Mass Index | -0.12 ± 1.66 |
Change in perceived stress scale score between baseline and post-intervention, pre-post Scale is 0-40 with higher scores reflecting higher perceived stress.
| score on a scale | Mindfulness |
|---|---|
| Perceived Stress Scale Score | -8.45 ± 5.50 |
Change in serum fasting glucose between baseline and follow-up, pre - post
| mg/dl | Mindfulness |
|---|---|
| Fasting Glucose | 3.53 ± 9.57 |
Change from baseline to post-intervention in % glycated hemoglobin
| percentage of glycated hemoglobin | Mindfulness |
|---|---|
| Hemoglobin A1c | -0.03 ± 0.22 |
Change in systolic blood pressure between baseline and post-intervention, pre - post
| mmHg | Mindfulness |
|---|---|
| Systolic Blood Pressure mmHg | -9.22 ± 12.62 |
Change in diastolic blood pressure between baseline and post-intervention, pre - post
| mmHg | Mindfulness |
|---|---|
| Diastolic Blood Pressure, mmHg | -1.32 ± 8.45 |
Collected over From baseline to post-intervention data collection, up to 9 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mindfulness | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Age, Continuous(years) | Mindfulness |
|---|---|
| Mean | 55.62 ± 5.83 |
| Sex: Female, Male(Participants) | Mindfulness |
|---|---|
| Female | 24 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | Mindfulness |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 24 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2024 to primary completion in Jul 2025, 11 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's 11 months is below that.
Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois Chicago